The U.S. Food and Drug Administration today denied a request for use of a qualified health claim that consumption of vitamin D may reduce the risk of developing multiple sclerosis （MS）， a chronic autoimmune disorder that damages the body's central nervous system.
The FDA thoroughly reviewed the 85 publications submitted by the Burdock Group on behalf of Bayer, as well as all the publications cited in the petition's appendix. The agency also conducted a vast independent literature review of hundreds of additional publications. Through this rigorous assessment, the FDA determined that scientific conclusions could not be drawn about the relationship between vitamin D intake and MS risk. based on the agency's review of the totality of publicly available scientific evidence, the FDA has concluded that there is no credible evidence of a relationship between intake of vitamin D and a reduced risk of MS.